Design of polyPEPTIdes diblock copolymers as emulsifiers to produce safe, controlled and reliable novel stimuli-responsive nanoCAPSules for skin care applications
Akronym
PEPTICAPS
Bidragets beskrivning
PeptiCaps aims at producing and validating a new family of stimuli-responsive nanocapsules able to encapsulate efficiently and protect specific active ingredients for skin care application. Those nanocapsules will be assembled by nanoemulsion technique using amphiphilic and biocompatible polypeptides diblock copolymers with one hydrophilic poly(ethylene glycol) block and one hydrophobic polypeptide block. Adjustment of the length of each block to finely tune the hydrophilic/Lipophilic balance of the macroemulsifier will allow the encapsulation of either hydrophobic or hydrophilic active ingredients. In addition, polypeptides block will be specifically designed to respond to changes in pH and the presence of enzyme occurring for the skin conditions targeted to allow a triggered release of the active ingredient. After scaling-up selected macroemulsifiers under GMP-like process, two manufacturing processes will be used for the production of the nanocapsules, i.e. high-pressure homogenizer and tubular flow contactor. The most promising process will be selected to produce selected nanocapsules. Physico-chemical properties and (eco)toxicity of the nanocapsules will be extensively characterised using techniques and protocols recommended by the EU Cosmetic regulation to establish their risk and safety assessment. The advantages of safe nanocapsules from PeptiCaps will be demonstrated on validated relevant skin models for each application. All results obtained will be gathered to constitute a Dossier for the validation of the nanocapsules as cosmetic product by the authorities. In addition, PeptiCaps will actively participate to the standardization for nano-safety by developing software to predict the toxicity of nanomaterials (CORAL). Finally, a business plan will be elaborated for the commercialization of PeptiCaps nanocapsules for all cosmetic applications as well as other markets (dermatology and food) to ensure full exploitation of the PeptiCaps technology.
Visa merStartår
2015
Slutår
2018
Beviljade finansiering
SPINVERSE OY
222 867.5 €
Participant
UNIVERSITE DE BORDEAUX (FR)
272 500 €
Participant
ANGEL CONSULTING SAS DI MATTEO ZANOTTI RUSSO & C (IT)
147 500 €
Participant
POLYPEPTIDE THERAPEUTIC SOLUTIONS SL (ES)
482 875 €
Participant
INSTITUT POLYTECHNIQUE DE BORDEAUX (FR)
97 825 €
Third party
FUNDACION CIDETEC (ES)
895 000 €
Coordinator
AHAVA DEAD SEA LABORATORIES LTD (IL)
371 522.5 €
Participant
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI (IT)
435 500 €
Participant
UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA (ES)
460 656.25 €
Participant
UNIVERSITE LYON 1 CLAUDE BERNARD (FR)
288 447.5 €
Participant
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR)
46 953.75 €
Third party
Beviljat belopp
3 852 294 €
Finansiär
Europeiska unionen
Typ av finansiering
Research and Innovation action
Ramprogram
Horizon 2020 Framework Programme
Utlysning
Programdel
INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies (5250 Ensuring the safe and sustainable development and application of nanotechnologies (5252 )
Developing the societal dimension of nanotechnology (5253 )
Developing and standardisation of capacity-enhancing techniques, measuring methods and equipment (5255 )
Tema
Novel nanomatrices and nanocapsules (NMP-06-2015Utlysnings ID
H2020-NMP-PILOTS-2015 Övriga uppgifter
Finansieringsbeslutets nummer
686141
Identifierade teman
materials, nanomaterials